Contrive Datum Insights has published "Cannabinoids Market Size, Share & Industry Analysis, By Cannabinoid type (Cannabidiol (CBD), Tetrahydrocannabinol (THC), Cannabigerol (CBG), Cannabinol (CBN), Cannabichromene (CBC), Cannabidiolic Acid (CBDA), Other Cannabinoids), Source (Hemp-Derived, Marijuana-Derived, Synthetic, Semi-Synthetic (Converted)), Product form (Isolate, Distillate, Crude Extract, Oils and Tinctures, Capsules and Softgels, Edibles, Topicals, Vapes and Inhalables), Extraction method (CO2 Extraction, Solvent Extraction, Solventless Extraction, Chemical Synthesis and Biosynthesis), Application (Pharmaceuticals, Nutraceuticals and Dietary Supplements, Food and Beverages, Cosmetics and Personal Care, Recreational and Adult Use, Pet and Veterinary Products, Research and Others), Spectrum profile (Full-Spectrum, Broad-Spectrum, Isolate (Single Molecule)), Purity grade (Pharmaceutical Grade, Food and Nutraceutical Grade, Cosmetic Grade, Industrial and Research Grade), Route of administration (Oral, Topical and Transdermal, Inhalation, Oromucosal Spray, Others), Distribution channel (Pharmacies and Drug Stores, Licensed Dispensaries, Online and E-commerce, Specialty and Health Stores, Business-to-Business Bulk Supply), Legal status (Prescription (Approved Drugs), Medical Cannabis Programmes, Adult-Use Regulated, Hemp-Derived Consumer Wellness), and Regional Forecast, 2026-2034". The study sizes the global cannabinoids market at USD 25.44 billion in 2025 and projects growth from USD 25.621 billion in 2026 to USD 28.804 billion by 2034, a compound annual growth rate of 1.5% across the forecast period.
Cannabinoids are the active compounds of the cannabis and hemp plants, supplied as isolated molecules, distillates and extracts, or produced by chemical synthesis and fermentation. They are sold as pharmaceutical ingredients and approved drugs, as nutraceutical and cosmetic ingredients, and as finished consumer products such as oils, capsules, edibles, topicals and inhalables. Buyers include drug makers, supplement and beverage brands, personal care companies, licensed retailers, pharmacies and patients under medical programmes.
US state-legal market growth outside California and California's 2025 recovery
US state-legal market growth outside California and California's 2025 recovery is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 1.5% a year, the cannabinoid type lines exposed to it move fastest: Tetrahydrocannabinol (THC) compounds at 3.4%, taking its share of revenue from 70.7% to 84.6% and its value from USD 17.99 billion to USD 24.375 billion.
On the upside, the study's bull case assumes every forecast factor at the upper end of its stated range: drivers faster, restraints milder, which would take 2034 revenue to USD 35.914 billion against the USD 28.804 billion base case.
On the downside, every forecast factor at the lower end of its stated range: drivers slower, restraints stronger, which would hold 2034 revenue to USD 23.394 billion. Cannabidiol (CBD), which carries 14.2% of 2025 revenue, already grows at only 0.4% against the market's 1.5%, so the largest part of the base is also its slowest.
Where the Competition Actually Sits
The cannabinoid type axis divides the field, and one line dominates both halves of it. Tetrahydrocannabinol (THC) is the largest at 70.7% of 2025 revenue, worth USD 17.99 billion, and also the fastest at 3.4%, ending 2034 at 84.6%. Incumbency and momentum are not split between rivals here, leaving the position hard to attack.
Other Findings in the Study
| Segment | Led 2025 by | Share & value | Fastest-growing |
|---|---|---|---|
| Cannabinoid type | Tetrahydrocannabinol (THC) | 70.7% · USD 17.99 billion | — |
| Source | Hemp-Derived | 48% · USD 12.211 billion | Synthetic 7% |
| Product form | Oils and Tinctures | 27% · USD 6.869 billion | Vapes and Inhalables 9.5% |
| Extraction method | Solvent Extraction | 42% · USD 10.685 billion | Solventless Extraction 6.1% |
| Application | Pharmaceuticals | 30% · USD 7.632 billion | — |
| Spectrum profile | Full-Spectrum | 46% · USD 11.702 billion | Broad-Spectrum 2.5% |
| Purity grade | Food and Nutraceutical Grade | 46% · USD 11.703 billion | Pharmaceutical Grade 5.7% |
| Route of administration | Oral | 44% · USD 11.194 billion | Oromucosal Spray 3.9% |
| Distribution channel | Licensed Dispensaries | 30% · USD 7.632 billion | Online and E-commerce 3.7% |
| Legal status | Hemp-Derived Consumer Wellness | 34% · USD 8.65 billion | Prescription (Approved Drugs) 5.3% |
- North America was the largest region in 2025, holding 86.9% of global revenue at USD 22.104 billion and reaching USD 22.613 billion by 2034.
- Europe takes a rising share of global revenue over the forecast period, from 9.2% in 2025 to 16% in 2034, with revenue growing from USD 2.353 billion to USD 4.619 billion.
- At 0.5% of 2025 revenue and 0.7% by 2034, Middle East and Africa is the smallest region throughout.
- No cannabinoid type line grows faster than Tetrahydrocannabinol (THC), at a projected 3.4%.
- The United States is the largest single country market at USD 19.341 billion in 2025, 76% of global revenue.
Every year from 2020 to 2034 is reported, with revenue and growth for each line across ten axes: by cannabinoid type, and by source, product form, extraction method, application, spectrum profile, purity grade, route of administration, distribution channel and legal status. The headline total carries bear, base and bull cases at USD 23.394 billion and USD 35.914 billion by 2034. The study also breaks out all five regions to country level, sets out the competitive landscape, and documents the method behind every estimate. Available as a PDF, with a free sample on request.